CAP-0121 / Califia Pharma - LARVOL DELTA

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the illudofulvene drug CAP-0121. (ASCO 2024) - "Further investigation in clinical trials is warranted to confirm these preclinical observations."

Clinical • PK/PD data • Hematological Disorders • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Thrombocytopenia

Safety, efficacy, pharmacokinetics, and pharmacodynamics of a second generation Irofulven analog CAP-0121 in preclinical cancer models (AACR 2024) - "The canine PK/PD study of CAP-121 demonstrates that CAP-121 has favorable PK parameters. With regards to in vivo anticancer cytotoxic activity, the two drug-resistant xenograft models confirm the superiority of CAP-121 over irofulven. Together, these findings indicate a wider therapeutic window in humans is expected for CAP-121 compared to irofulven, emphasizing the potential anticancer utility of CAP-121 for solid cancers without prolonged thrombocytopenia."

PK/PD data • Preclinical • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Preclinical evaluation of CAP-0121 for multidrug resistant cancers (AACR 2022) - "This response of CAP-0121 in drug resistant xenografts is observed at nontoxic doses. Synergistic action is observed when CAP-0121 is administered in combination with traditional drugs used for treating ovarian cancer, including taxanes, platinum agents, and PARP inhibitors."

Preclinical • Hepatocellular Cancer • Oncology • Ovarian Cancer • Solid Tumor • ABCB1